IL28B) [8-10]. Participants with no tertiary education were less likely to have 80/80 PEG-IFN adherence (AOR 0.29,P=0.045). IDU prior to or during treatment did not effect 80/80 PEG-IFN adherence. SVR MK-8245 Trifluoroacetate was higher among those with 80/80 PEG-IFN adherence (67% vs. 35%,P=0.007), but similar among those with and without missed doses during therapy (73% vs. 60%,P=0.309). SVR in those discontinuing therapy between 0-4, 5-19, 20-23 and 24 weeks was 9%, 33%, 43% and 76%, respectively (P<0.001). == Summary == Large adherence to treatment for recent HCV was observed, irrespective of IDU prior to, or during, therapy. Sub-optimal PEG-IFN exposure was primarily driven by early treatment discontinuation rather than missed doses during therapy. Keywords:injection drug users, HIV illness, discontinuation, pegylated interferon, therapy == Intro == Pegylated interferon (PEG-IFN) and ribavirin for the treatment of chronic MK-8245 Trifluoroacetate hepatitis C computer virus (HCV) illness is effective in 54-56% and 27-40% of individuals with HCV [1-3] and HCV/HIV, respectively [4-5]. Sustained virological response (SVR) is definitely associated with more youthful age [1-2], HCV genotype [1-3], HCV RNA [1,3], HCV viral kinetics [6-7], fibrosis [1] and sponsor genetics (e.g. IL28B) [8-10]. Adherence to therapy is also important and enhances SVR [11-14]. However, studies of adherence are limited by the restricted populations, small sample sizes and varying adherence meanings [14]. Treatment response is also higher among individuals with recent HCV. Response rates range from 57-88% among HCV individuals receiving 12-24 weeks of therapy with PEG-IFN monotherapy [15-22] and from 59-74% among HCV/HIV individuals receiving 12-24 weeks of therapy with PEG-IFN and ribavirin [22-24]. In the Australian Trial in Acute Hepatitis C (ATAHC), SVR rates of 55% and 74% for HCV (PEG-IFN) and HCV/HIV participants (PEG-IFN/ribavirin) were observed after 24 weeks of therapy, respectively [22]. Among HCV participants, SVR was higher among those adherent to PEG-IFN (63% vs. 29%,P=0.025) [22]. Among those ever having injected medicines (n=63), SVR was related for those participants who did and did not inject during treatment (59% vs. 53%,P=0.76) and was not related to injecting rate of recurrence [22]. Among healthcare providers, there are still issues about the suitability of HCV treatment in IDUs, due to patient motivation and adherence, psychosocial issues, medical and psychiatric comorbidities, re-infection risk and the lack of infrastructure to ensure access to care [25]. However, response rates among IDUs are comparable to non-IDUs [26]. But, little is known about adherence to HCV therapy and connected factors, particularly among IDUs and those with recently acquired HCV. The ATAHC study was designed specifically to investigate treatment for recent HCV, mainly in those with IDU-acquired illness. The study distinctively recruited both HCV and HCV/HIV participants under the same protocol. Here, we statement within the adherence to PEG-IFN and predictors of adherence with this study. == Methods == == Study design == ATAHC was a multicenter, prospective cohort study of the natural history and treatment of recent HCV illness, as previously described [22]. Recruitment of HIV infected and uninfected participants was from June 2004 through November 2007 through an Australian network of tertiary private hospitals (n=13) and general practice/main care clinics (n=3). The top five sites in Sydney (n=2), Melbourne (n=2) and Adelaide COL18A1 (n=1) recruited 84% of participants. Recent illness with either acute or early chronic HCV illness with the following eligibility criteria: First positive anti-HCV antibody within 6 months of enrolment;and either Acute clinical hepatitis C illness, defined as symptomatic seroconversion illness or alanine aminotransferase (ALT) level greater than 10 occasions the top limit of normal (>400 IU/L) with exclusion of other causes of acute hepatitis, at most 12 months before the initial positive anti-HCV antibody;or Asymptomatic hepatitis C infection with seroconversion, defined by a negative anti-HCV antibody in the two years prior to the initial positive anti-HCV antibody. All participants with HCV RNA during the screening period (maximum 12 weeks) were assessed for HCV MK-8245 Trifluoroacetate treatment MK-8245 Trifluoroacetate eligibility. Heavy alcohol intake and active drug use were not exclusion criteria. From screening, participants were followed for up to 12 weeks to allow for spontaneous HCV clearance and if HCV RNA remained detectable were offered treatment. Participants were then seen at baseline and 12 weekly intervals for up.